LPCN 2201 – Major Depressive Disorder
Oral Rapid Acting Anti-depressant (RAAD)
Novel MOA/Treatment Paradigm
Superior tolerability
Product Candidate: LPCN 2201
Oral Rapid Acting Anti-depressant (RAAD) for Major Depressive Disorders (MDD)
Product Attributes:
A novel MOA with superior benefit to risk profile and less label encumbrance than conventional antidepressant.
LPCN 2201, oral Brexanolone, is chemically identical to the endogenous human hormone allopregnanolone, a positive allosteric modulator of y-aminobutyric acid (GABAA) receptor.
LPCN 2201 is being developed to provide a novel, rapid relief oral treatment option for major depressive depression (MDD), aiming to improve outcomes without the limitations of existing therapies.
Promoting acute stabilization of symptoms with freedom of “at home” dosing while presenting no significant risk of adverse reactions from exposure to bioidentical brexanolone.
LPCN 2201 is an appealing option for patients with MDD and suicidal ideation and in whom rapid improvement is a priority.
About Indication:
Depression is one of the leading drivers of workplace productivity loss worldwide.
Major depressive disorder (MDD), also known as clinical depression, affects approximately 21 million adults in the U.S., representing 8.4% of the population.
Clinical depression symptoms may include depressed mood, loss of interest in daily activities, change in sleep, appetite or weight, fatigue, diminished concentration or slowed thoughts, feelings of worthlessness and/or suicidal ideation.
In 2018, the total annual burden of medication-treated MDD in the U.S. was $92.7 billion.
Patients often express concerns related to the inadequacy of available treatments, incomplete treatment response, and the side effect burden of available major depressive disorder (MDD) treatments
Newer MDD rapid relief options, such as SPRAVATO®(esketamine), come with significant cost burdens and face significant challenges. Spravato® comes with serious safety concerns, including black box warnings for sedation, dissociation, cognitive impairment, and increased blood pressure. Beyond safety, access remains a major hurdle—esketamine, for example, requires intranasal administration in a clinical setting under a restricted program, limiting convenience and scalability.
Patients and providers urgently need a convenient, well-tolerated, at-home rapid relief option for MDD. Ideal solutions should offer ease of use without monitoring requirements, enabling treatment in outpatient or home settings.
A preferred Rapid Acting Anti-depressant is expected to deliver effective antidepressant action with high and sustained remission rates, while maintaining a wide therapeutic index for safety and tolerability. Improved compliance, better management of comorbid conditions such as anxiety, and enhanced patient experience are critical to addressing the gaps left by current therapies.